New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

BACKGROUND: Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively. It was granted marketing authorization in India in 2013 for diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaul, Upendra, Parmar, Deven, Manjunath, K., Shah, Mitesh, Parmar, Krupi, Patil, Kishor P., Jaiswal, Ashok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580520/
https://www.ncbi.nlm.nih.gov/pubmed/31208414
http://dx.doi.org/10.1186/s12933-019-0884-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580520/
https://www.ncbi.nlm.nih.gov/pubmed/31208414
http://dx.doi.org/10.1186/s12933-019-0884-3

Ejemplares similares